It has recently been announced that the creation of a drug molecule, developed through purely artificial intelligence (AI), will be used in tests on humans. The result is part of a partnership between the British startup Exscientia, focused on biotechnology, and the Japanese pharmaceutical company Sumitomo Dainippon Pharma. The drug was created to treat people who have obsessive-compulsive disorder (OCD) and its compound was discovered through Exscientia systems.
A drug takes 4 ½ years to begin testing in humans, but with AI possible in less than 12 months
Typically, to reach the stage of clinical testing in humans, a drug takes approximately 4 ½ years. However, using AI tools, it is possible, according to Exscientia, to reach this level in just 12 months or even less. The drug, called DSP-1181, was developed through the use of algorithms to filter possible compounds and compare them with a huge parameter database, which includes, for example, a patient's genetics.
We have reached a critical milestone in the development of #AI and medicine. With Sumitomo Dainippon Pharma, we have developed the first drug created by #AI to enter human clinical trials. Read more here: https://t.co/vQF95x3Nk6
– Exscientia (@exscientialtd) January 30, 2020
During an interview by the BBC, Exscientia chief professor Andrew Hopkins says:
"a key milestone in drug discovery."
Andrew adds by saying:
"We have seen diagnoses of patients using AI, in addition to analyzing data and examining people, but what we did was use AI directly to create a new drug. Billions of decisions are needed to find the right molecules and a decision It is huge to design a drug with precision. But the beauty of the algorithm is that they are agnostic, so they can be applied to any disease. "
Exscientia says it is already developing drugs for cancer and cardiovascular diseases
The newly developed drug enters the testing phase in Japan, and if they are well accepted, I will proceed to tests around the world. The company says it is already working on drugs for the treatment of cancer and cardiovascular diseases. The expectation that by the end of the year the company already has another molecule ready for clinical tests.
The chief executive of the Cancer Research Institute, Paul Workman, did not participate in the research, but said:
"I think AI has enormous potential to improve and accelerate drug discovery. I am excited to see what I believe is the first example of a new drug that is now entering clinical trials in humans, created by scientists using AI in an important way to guide and accelerate discoveries. "
How to accept drugs created by machines with artificial intelligence?
With the arrival of medicines created by machines with artificial intelligence, we will face a change in paradigms and consequently there will be a need to change the way of thinking. It is likely that during tests with the drug to treat OCD, DSP-1181, face resistance by some patients, after all, something very different. Anyway, it is precisely for this and other aspects that experiments are carried out before being released for commercialization.
Source: exscientia, Engadget, BBC
We recommend reading: